HighTide Therapeutics-B (2511) Schedules 27 March 2026 Board Meeting to Approve FY 2025 Audited Results

Bulletin Express
Mar 13

HighTide Therapeutics, Inc. (HIGHTIDE-B, 2511) has announced that its board of directors will convene on Friday, 27 March 2026. The primary agenda is to review and approve the audited consolidated financial results for the year ended 31 December 2025 and authorise their publication. Additional routine business matters may also be addressed at the meeting.

The board currently consists of two executive directors (Dr. Liu Liping and Ms. Yu Meng), three non-executive directors (Dr. Zhu Xun, Mr. Ma Lixiong and Mr. Jiang Feng) and three independent non-executive directors (Mr. Tan Bo, Dr. Li Jin and Mr. Hung Tak Wai).

The company will disclose the audited annual results following board approval on the scheduled date.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10